爱尔兰爵士制药的defiteli说明书

Instructions for Irish Jazz Pharmaceuticals:

Indications:

Defiteli is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Dosage and Administration:

The recommended dose of defiteli for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days. Defiteli must be diluted before infusion.

Things to note:

Bleeding: Concomitant use of defiteli and a systemic anticoagulant or fibrinolytic therapy (excluding use for routine maintenance or central venous line reopening) may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before defibrotide therapy, and consider delaying initiation of defibrotide administration until the effects of the anticoagulant have lessened.

2. Hypersensitivity reactions: Hypersensitivity reactions have occurred in less than 2% of patients treated with defibrotide (). These reactions include rash, urticaria, and angioedema. One case of anaphylactic reaction was reported in a patient who had previously received defibrotide. Monitor patients for hypersensitivity reactions. Especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue defibrotide, treat with standard medical care, and monitor until symptoms resolve.

Recommended related hot articles: /newsDetail/95243.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.